SCHEMBL71526

SCHEMBL71526

Cc1ccc(C(=O)Cl)cc1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.58
RXRB P28702 2/20 0.58
RXRG P48443 1/20 0.58
GLRA1 P23415 1/20 0.53
HPGD P15428 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
SMPD1 P17405 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
FFAR4 Q5NUL3 2/20 0.50
BRD4 O60885 2/20 0.48
MCL1 Q07820 1/20 0.48
MRGPRX4 Q96LA9 2/20 0.48
FFAR1 O14842 1/20 0.48
MAOB P27338 1/20 0.48
PTPN1 P18031 1/20 0.47
SLC22A12 Q96S37 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7783922 0.88 FFAR4 (0.60) RXRARXRBRXRGGLRA1HPGD
SCHEMBL69666 0.88 RXRA (0.70) RXRARXRBRXRGHPGDNPC1
SCHEMBL1599431 0.86 HPGD (0.59) RXRARXRBGLRA1HPGDNPC1
SCHEMBL29557477 0.86 HPGD (0.59) RXRARXRBGLRA1HPGDNPC1
SCHEMBL71773 0.85 PARP10 (0.59) RXRARXRBRXRGHPGDNPC1
SCHEMBL69503 0.84 RXRA (0.57) RXRARXRBRXRGHPGDNPC1
SCHEMBL16929834 0.84 LMNA (0.59) RXRARXRBRXRGHPGDNPC1
SCHEMBL31241237 0.84 LMNA (0.59) RXRARXRBRXRGHPGDNPC1
SCHEMBL6356140 0.84 GLRA1 (0.56) RXRARXRBRXRGGLRA1HPGD
SCHEMBL184987 0.84 SMPD1 (0.71) RXRAHPGDNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed
US-5677112-A USING AN ANTHRACENE COMPOUND WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-14 US disclosed
EP-0635480-B1 Anthracene derivatives WAKO PURE CHEM IND LTD (JP) 1997-03-19 EP disclosed
US-5576359-A ANTHRACENE DERIVATIVE, SOLVENT, COMPOUND CONTAINING GLYCIDYL GROUPS WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1996-11-19 US disclosed
EP-0636941-B1 Deep ultraviolet absorbent and its use in pattern formation WAKO PURE CHEM IND LTD (JP) 1996-03-20 EP disclosed
US-5498748-A PHENOLIC CROSSLINKER FOR A POLYGLYCIDYL METHACRYLATE TO FORM A MATERIAL USED AS AN ANTIREFLECTION COATING FOR DEEP UV LIGHT SUCH AS KRF EXIMER LASERS IN SEMICONDUCTOR PHOTORESISTS WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1996-03-12 US disclosed
EP-0636941-A1 Deep ultraviolet absorbent and its use in pattern formation WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1995-02-01 EP disclosed
EP-0635480-A1 Anthracene derivatives WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1995-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 RXRA 1461/4885RXRB 1194/4885RXRG 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.